EGFR and neoplasm: To assess whether antibody affinity affects the capacity to promote effector functions, anti-EGFR and anti-HER2 variants were tested for their ability to mediate ADCC against a panel of tumor cell lines expressing diverse levels of EGFR and HER2 antigens.